Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Feb 20

PMID 24551091

Citations 16

Authors

Kristina A Williams

Kathryn L Terry

Shelley S Tworoger

Allison F Vitonis

Linda J Titus

Daniel W Cramer

Affiliations

Soon will be listed here.

Abstract

Objective: To examine single nucleotide polymorphism (SNPs) in MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival.

Methods: We genotyped germline variants of MUC16 (rs2547065, rs1559168, rs12984471, rs2121133) and MUC1 (rs2070803, rs4072037, rs1045253) using samples collected from 758 ovarian cancer cases and 788 controls enrolled in the New England Case-Control Study between 2003 and 2008. We calculated age-adjusted odds ratios (OR) and 95% confidence intervals (CIs) for disease risk using unconditional and polytomous logistic regression and hazard ratios (HR) for survival using Cox proportional hazard ratios. In a subset of cases, we compared log-normalized CA125 values by genotype using generalized linear models.

Results: Cases homozygous for the variant allele of MUC16 SNP, rs12984471, had poorer overall survival (log-rank p = 0.03) and higher CA125 levels, especially cases over age 65 (p = 0.01). For MUC1 SNP, rs4072037, women homozygous for the G variant had a non-significantly decreased risk for serous invasive types but elevated risk for serous borderline tumors, mucinous borderline and invasive tumors, and endometrioid tumors. Women with the variant allele of MUC16 SNP, rs2547065, especially those who were homozygous had an elevated risk for ovarian cancer; but this association was not confirmed in an independent dataset.

Conclusion: This targeted screen of seven polymorphisms of MUC16 and MUC1 genes failed to identify and confirm effects on ovarian cancer risk overall. However, there may be effects of MUC16 rs12984471 on survival and MUC1 rs4072037 on risk for histologic types of ovarian cancer other than invasive serous. Further study is warranted.

Citing Articles

Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors.

Pandya P, Jannu A, Bijangi-Vishehsaraei K, Dobrota E, Bailey B, Barghi F Cancers (Basel). 2023; 15(1).

PMID: 36612255 PMC: 9818438. DOI: 10.3390/cancers15010259.

Establishment of an optimized CTC detection model consisting of EpCAM, MUC1 and WT1 in epithelial ovarian cancer and its correlation with clinical characteristics.

Wang T, Gao Y, Wang X, Tian J, Li Y, Yu B Chin J Cancer Res. 2022; 34(2):95-108.

PMID: 35685992 PMC: 9086574. DOI: 10.21147/j.issn.1000-9604.2022.02.04.

The association between single nucleotide polymorphisms and ovarian cancer risk: A systematic review and network meta-analysis.

Hu J, Xu Z, Ye Z, Li J, Hao Z, Wang Y Cancer Med. 2022; 12(1):541-556.

PMID: 35637613 PMC: 9844622. DOI: 10.1002/cam4.4891.

Genome-wide association study of serum tumor markers in Southern Chinese Han population.

Li X, Bai F, Wei X, Jin T, Li C, Zhang Y BMC Cancer. 2022; 22(1):160.

PMID: 35144566 PMC: 8832811. DOI: 10.1186/s12885-022-09236-6.

Radiomics based on multisequence magnetic resonance imaging for the preoperative prediction of peritoneal metastasis in ovarian cancer.

Song X, Ren J, Yao T, Zhao D, Niu J Eur Radiol. 2021; 31(11):8438-8446.

PMID: 33948702 DOI: 10.1007/s00330-021-08004-7.

References

Waltz M, Pandelidis S, Pratt W, Barnes D, Swallow D, Gendler S . A microsatellite within the MUC1 locus at 1q21 is altered in the neoplastic cells of breast cancer patients. Cancer Genet Cytogenet. 1997; 100(1):63-7. DOI: 10.1016/s0165-4608(97)00015-0. View

Phelan C, Tsai Y, Goode E, Vierkant R, Fridley B, Beesley J . Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2010; 19(2):600-4. PMC: 2880167. DOI: 10.1158/1055-9965.EPI-09-0861. View

Shi Y, Hu Z, Wu C, Dai J, Li H, Dong J . A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat Genet. 2011; 43(12):1215-8. DOI: 10.1038/ng.978. View

Giuntoli 2nd R, Rodriguez G, Whitaker R, Dodge R, Voynow J . Mucin gene expression in ovarian cancers. Cancer Res. 1998; 58(23):5546-50. View

Terry K, Vitonis A, Hernandez D, Lurie G, Song H, Ramus S . A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies. Int J Mol Epidemiol Genet. 2011; 1(4):272-7. PMC: 3076782. View

Bast Jr R, Klug T, St John E, Jenison E, Niloff J, Lazarus H . A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309(15):883-7. DOI: 10.1056/NEJM198310133091503. View

Vitonis A, Titus-Ernstoff L, Cramer D . Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy. Obstet Gynecol. 2011; 117(5):1042-1050. PMC: 3781934. DOI: 10.1097/AOG.0b013e318212fcb7. View

Micci F, Weimer J, Haugom L, Skotheim R, Grunewald R, Abeler V . Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. Genes Chromosomes Cancer. 2008; 48(2):184-93. DOI: 10.1002/gcc.20628. View

Ng W, Loh A, Teixeira A, Pereira S, Swallow D . Genetic regulation of MUC1 alternative splicing in human tissues. Br J Cancer. 2009; 99(6):978-85. PMC: 2538764. DOI: 10.1038/sj.bjc.6604617. View

10.

Tashiro Y, Yonezawa S, Kim Y, Sato E . Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum Pathol. 1994; 25(4):364-72. DOI: 10.1016/0046-8177(94)90144-9. View

11.

Bouanene H, Hadj Kacem H, Ben Fatma L, Limem H, Ben Ahmed S, Yakoub S . Polymorphisms in the MUC16 gene: potential implication in epithelial ovarian cancer. Pathol Oncol Res. 2010; 17(2):295-9. DOI: 10.1007/s12253-010-9314-2. View

12.

Buller R, Berman M, Bloss J, Manetta A, Disaia P . Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol. 1992; 47(1):87-92. DOI: 10.1016/0090-8258(92)90082-t. View

13.

Tothill R, Tinker A, George J, Brown R, Fox S, Lade S . Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14(16):5198-208. DOI: 10.1158/1078-0432.CCR-08-0196. View

14.

Schroeder J, Masri A, Adriance M, Tessier J, Kotlarczyk K, Thompson M . MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene. 2004; 23(34):5739-47. DOI: 10.1038/sj.onc.1207713. View

15.

Sherry S, Ward M, Kholodov M, Baker J, Phan L, Smigielski E . dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2000; 29(1):308-11. PMC: 29783. DOI: 10.1093/nar/29.1.308. View

16.

Palmer A, Lochhead P, Hold G, Rabkin C, Chow W, Lissowska J . Genetic variation in C20orf54, PLCE1 and MUC1 and the risk of upper gastrointestinal cancers in Caucasian populations. Eur J Cancer Prev. 2012; 21(6):541-4. PMC: 3460062. DOI: 10.1097/CEJ.0b013e3283529b79. View

17.

Feng H, Ghazizadeh M, Konishi H, Araki T . Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol. 2003; 32(12):525-9. DOI: 10.1093/jjco/hyf111. View

18.

Lacunza E, Baudis M, Colussi A, Segal-Eiras A, Croce M, Abba M . MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet. 2010; 201(2):102-10. DOI: 10.1016/j.cancergencyto.2010.05.015. View

19.

Hattrup C, Gendler S . Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2007; 70:431-57. DOI: 10.1146/annurev.physiol.70.113006.100659. View

20.

Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I . MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol. 2011; 121(3):434-43. DOI: 10.1016/j.ygyno.2011.02.020. View